Basic new born and antenatal screening for aspirational districts: unique methods of management and treatment of inherited disorders
DOI:
https://doi.org/10.18203/2349-3291.ijcp20240092Keywords:
Antenatal screening, New born screening, UMMIDAbstract
Background: Early screening, diagnosis and management program can contribute in reducing the burden of genetic disorders which can lead to early neonatal death or long-term disability in the vulnerable areas. UMMID (Unique Methods of Management and treatment of Inherited Disorders) and NIDAN (National Inherited Diseases Administration), aimed at developing a community level program for need assessment and to evaluate the feasibility of basic screening for some genetic/endocrine disorders in high-risk population.
Methods: UMMID was carried out at the aspirational district Ranchi, Jharkhand for 3 years (2019-2022) to perform newborn screening (NBS) in <7 days old newborn babies for 5 metabolic disorders and to screen antenatal mothers for prevention of thalassemia and other hemoglobinopathies.
Results: G6PD deficiency being more prevalent in Ranchi district out of five metabolic disorders screened. 13.6% of screen positive cases were confirmed positive for hemoglobinopathies. c.20 A>T is the most common mutation found among carriers.
Conclusions: This initiative underscores the need of such screening programs in aspirational districts to manage and prevent these disorders effectively.
References
Choudhuri T, Sengupta S. Inborn errors of metabolism-an Indian perspective. Int J Hum Genet. 2006;6(1):89-91.
Verma IC, Bijarnia S. The burden of genetic disorders in India and a framework for community control. Community Genet. 2002;5(3):192-6.
Madan N, Sharma S, Sood SK, Colah R. Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India. Ind J Human Genet. 2010;16(1):16.
Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Executive summary. Newborn screening: toward a uniform screening panel and system. Genet Med. 2006;8(3):1S–252.
ICMR Task Force on Inherited Metabolic Disorders drseemakapoor@ gmail. com Rita Christopher A. Radha Rama Devi Madhulika Kabra Seema Kapoor Roli Mathur Mamta Muranjan Puneet K. Nigam RM Pandey Arun Singh S. Suresh. Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia. Ind J Pediatr. 2018;85:935-40.
Anand MR, Ramesh P, Nath D. Congenital hypothyroidism screening with umbilical cord blood: retrospective analysis. Ind Pediatr. 2015;52(5):435-6.
Kaur G, Srivastav J, Jain S, Chawla D, Chavan BS, Atwal R, et al. Preliminary report on neonatal screening for congenital hypothyroidism, congenital adrenal hyperplasia and glucose-6-phosphate dehydrogenase deficiency: a Chandigarh experience. Ind J Pediatr. 2010;77:969-73.
ICMR Task Force on Inherited Metabolic Disorders drseemakapoor@ gmail. com Rita Christopher A. Radha Rama Devi Madhulika Kabra Seema Kapoor Roli Mathur Mamta Muranjan Puneet K. Nigam RM Pandey Arun Singh S. Suresh. Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia. Ind J Pediatr. 2018;85:935-40.
Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. J Inherit Metab Dis. 1991;14(6):923-7.
Pyhtila BM, Shaw KA, Neumann SE, Fridovich-Keil JL. Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead. JIMD Rep. 2015;15:79-93.
Roy A, Samanta T, Purkait R, Mukherji A, Ganguly S. Etiology, clinical spectrum and outcome of metabolic liver diseases in children. J Coll Physicians Surg Pak. 2013;23(3):194-8.
Shanthi S, Beula D, Rajendran A, Ravichandran C, Shilpa S, Anuradha D. Antenatal screening for haemoglobinopathies among the tribal population in the state of Tamil Nadu, India. HemaSphere. 2023;7(S1):5.
Ahuja T, Bhatnagar N, Shah M, Shah S. Screening of antenatal patients for anaemia and haemoglobinopathies. Hematol Transfu Int J. 2023;11(3):67-71.
Ghosh S, Chakrabarti S, Bhattacharyya M. Prenatal screening and diagnosis of ß-thalassemia in India: Is ARMS-PCR enough? Ind J Hematol Blood Transfus. 2021;37(3):448-52.
Raveendran A, Chacko TJ, Prabhu P, Varma R, Lewis LE, Rao P, et al. Need and viability of newborn screening programme in India: report from a pilot study. Int J Neonat Scr. 2022;8(2):26.
Colah R, Surve R, Wadia M, Solanki P, Mayekar P, Thomas M, et al. Carrier screening for β-thalassemia during pregnancy in India: a 7-year evaluation. Genetic Test. 2008;12(2):181-5.
Cao Y, Yuan P, Wang YP, Mao M, Zhu J. The profile of newborn screening coverage in China. J Med Screen. 2009;16:163-6.
Agarwal M, Joshi K, Bhatia V, Gopalakrishnan V, Dabadghao P, Das V, et al. Feasibility study of an outreach program of newborn screening in Uttar Pradesh. Ind J Pediatr. 2015;82:427-32.
David-Padilla C, Dans LF, Tamondong Jr MR, Bernal RM, Laceste JJ, Capistrano-Estrada S. Cost-benefit analysis of the newborn screening program of the Philippines. Acta Medica Philippina. 2009;43(2).
Sinha S, Seth T, Colah RB, Bittles AH. Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017–2026. J Commu Genet. 2020;11(1):39-45.
California Department of Public Health. Newborn Screening Program (NBS). Available at: https://www.cdph.ca.gov/Programs/CFH/DGDS/Pages/nbs/default.aspx. Accessed 21 December 2019.
Ghotbi N, Tsukatani T. Evaluation of the national health policy of thalassaemia screening in the Islamic Republic of Iran. La Revue Sante Mediterr Orient. 2005;11(3):308-18.
Desai MP, Sharma R, Riaz I, Sudhanshu S, Parikh R, Bhatia V. Newborn screening guidelines for congenital hypothyroidism in India: recommendations of the Indian society for pediatric and adolescent endocrinology (ISPAE)–Part I: Screening and confirmation of diagnosis. Ind J Pediatr. 2018;85:440-7.
Godard B, Ten Kate L, Evers-Kiebooms G, Aymé S. Population genetic screening programmes: principles, techniques, practices, and policies. Euro J Human Genet. 2003;11(2):S49-87.
Mudiyanse RM. Thalassemia treatment and prevention in Uva province, Sri Lanka: a public opinion survey. Hemoglobin. 2006;30(2):275-89.
